dronedarone

The safety agency's latest advisory said that patients with a "permanent" version of the abnormal heartbeat called atrial fibrillation shouldn't get the medicine, generically called dronedarone.

FDA Further Restricts Use of Sanofi's Multaq Thomas M. Burton 2011

The French pharmaceutical company developed Multaq, generically known as dronedarone, as a treatment of a heart condition called atrial fibrillation, or irregular heartbeat.

FDA Hastens Sanofi Review 2008

The drug, also known as dronedarone, carries a black-box warning that it shouldn’t be used in patients who have recently had severe heart failure, because it can cause severe problems including death.

Atrial-Fibrillation Patients Have Increasing Options for Treatment 2009

"I am excited by the launch of dronedarone which is a valuable additional choice for the treatment of AF.

icLiverpool 2010

The FDA said that "since dronedarone's approval in July 2009 through October 2010, around 492,000 dronedarone prescriptions were dispensed and around 147,000 patients filled dronedarone prescriptions at outpatient retail pharmacies in the United States."

Two Patients on Sanofi's Multaq Have Liver Failure A H Mooradian 2011

Food and Drug Administration said it was "alerting health-care professionals and patients about cases of rare, but severe liver injury, including two cases of acute liver failure leading to liver transplant in patients treated with the heart medication dronedarone Multaq."

Two Patients on Sanofi's Multaq Have Liver Failure A H Mooradian 2011

Sanofi has forecast annual sales of more than €1 billion ($1.41 billion) for Multaq, generically known as dronedarone.

Amid Restructuring, Sanofi Gets FDA Nod for Heart Drug 2009

Sanofi still plans to resubmit the drug, dronedarone, for regulatory approval in the U.S. and Europe by the end of September because a more recent study suggested the drug reduced the risk of death in patients with a heart condition known as atrial fibrillation, or irregular heartbeat.

Sanofi to Resubmit Heart Drug 2008

I'll cite just one very recent and ongoing example: dronedarone Multaq, which is a case study of all that can go wrong when conflicts of interest run amok.

unknown title 2011

In the updated label, the Food and Drug Administration said Multaq, known chemically as dronedarone, should not be used by patients who have permanent atrial fibrillation AF, a type of abnormal heart rhythm.

Reuters: Press Release 2011